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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 304, Revision 1 
(FGE.304Rev1): Four carboxamides from Chemical Groups 30
1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)
2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT  
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to evaluate four flavouring substances in the Flavouring Group Evaluation 304, 
Revision 1 (FGE.304Rev1) using the Procedure in Commission Regulation (EC) No 1565/2000. This revision is 
made due to a re-evaluation of one flavouring substance N-(2-(pyridine-2-yl)ethyl)-3-p-menthanecarboxamide 
[FL-no: 16.118], as a 90-day dietary rat study has become available. One of the original five flavouring 
substances [FL-no: 16.124], for which additional data were requested, is no longer supported by the Industry for 
use as flavouring substance in Europe and will therefore not be considered any further in FGE.304Rev1. 
Therefore, FGE.304Rev1 will deal with four flavouring substances. None of the four substances were considered 
to have genotoxic potential. The substances were evaluated through a stepwise approach (the Procedure) that 
integrates information on structure-activity relationships, intake from current uses, toxicological threshold of 
concern, and available data on metabolism and toxicity. The Panel concluded that the four substances [FL-no: 
16.117, 16.118, 16.123 and 16.125] do not give rise to safety concern at their levels of dietary intake, estimated 
on the basis of the MSDI approach. Besides the safety assessment of these flavouring substances, the 
specifications for the materials of commerce have also been considered. Specifications including complete purity 
criteria and identity for the materials of commerce have been provided for all four candidate substances. 
© European Food Safety Authority, 2014 
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SUMMARY  
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was asked to evaluate four flavouring substances in the 
Flavouring Group Evaluation 304, Revision 1 (FGE.304Rev1), using the Procedure as referred to in 
the Commission Regulation (EC) No 1565/2000. These four carboxamides [FL-no: 16.117, 16.118, 
16.123 and 16.125] belong to chemical group 30, Annex I of the Commission Regulation (EC) No 
1565/2000. 
The present Flavouring Group Evaluation deals with four carboxamides. Since the publication of the 
previous version, FGE.304, one of the original five candidate substances [FL-no: 16.124], for which 
additional data were required, is no longer supported by Industry for use as flavouring substance in 
Europa and will therefore not be considered any further. This revision of FGE.304, FGE.304Rev1, 
therefore only deals with four candidate substances N-p-benzeneacetonitrile-menthanecarboxamide 
[FL-no: 16.117], N-(2-(pyridine-2-yl)ethyl)-3-p-menthanecarboxamide [FL-no: 16.118], (1R,2S,5R)-
N-(4-methoxyphenyl)-5-methyl-2-(1-methylethyl)cyclohexanecarboxamide [FL-no: 16.123] and 
(2S,5R)-N-[4-(2-amino-2-oxoethyl)phenyl]-5-methyl-2-(propan-2-yl)cyclohexanecarboxamide [FL-
no: 16.125]. 
Further, the present revision of FGE.304, FGE.304Rev1, includes the assessment of new toxicity data 
on  N-(2-(pyridine-2-yl)ethyl)-3-p-menthanecarboxamide [FL-no: 16.118] for which additional data 
were required. 
The four flavouring substances possess chiral centres. All substances have been presented with 
specification of the stereoisomeric composition. 
All candidate substances were assigned to structural class III, according to the decision tree approach 
presented by Cramer et al., 1978. 
None of the candidate substances have been reported to occur naturally. 
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavouring Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach.  
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
Genotoxicity data are available for three substances. The Panel concluded that the data available do 
not give rise to safety concern with respect to genotoxicity for any of the candidate substances. 
On the basis of the available data, the hydrolysis of the candidate substances cannot be excluded. 
However, owing to the lack of further data, the candidate substances cannot be anticipated to be 
metabolised to innocuous products. Flavouring Group Evaluation 304 Revision 1
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According to the default MSDI approach, the three flavouring substances [FL-no: 16.118, 16.123 and 
16.125] in this group have intakes in Europe from 6.1 to 61 µg/capita/day, which are below the 
threshold of concern value for structural class III of 90 µg/person/day. For the remaining substance 
[FL-no: 16.117] the intake of 120 µg/capita/day is above the threshold of concern. However, an 
adequate NOAEL of 100 mg/kg body weight/day exists from a 90-day study with this candidate 
substance [FL-no: 16.117], which provides a margin of safety of 5 x 10
4. This substance is structurally 
related to the two substances [FL-no: 16.123 and 16.125] for which a margin of safety of 3.3 x 10
5, 
based on the combined estimated daily per capita intake, can be calculated.  For the remaining 
candidate substance [FL-no: 16.118] a 90-day study has become available and a NOAEL to provide 
adequate margin of safety of 5000 is derived. Therefore, the four substances [FL-no: 16.117, 16.118, 
16.123 and 16.125] are not anticipated to pose a safety concern when used as flavouring substances at 
the estimated levels of intake, based on the MSDI approach. 
In order to determine whether the conclusion for the four flavouring substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate specifications 
including complete purity criteria and identity for the materials of commerce have been provided for 
all the flavouring substances evaluated through the Procedure. Thus, the final evaluation of the 
materials of commerce can be performed for all four substances. 
In conclusion, for all substances [FL-no: 16.117, 16.118, 16.123 and 16.125], the Panel concluded that 
they would present no safety concern at the estimated levels of intake based on the MSDI approach. 
However, when the estimated intakes were based on the mTAMDI approach, they ranged from 150 to 
7800 µg/person/day for the four candidate substances from structural class III, which are above the 
threshold of concern for structural class III of 90 µg/person/day. Therefore more reliable exposure data 
are required for these substances [FL-no: 16.117, 16.118, 16.123 and 16.125]. On the basis of such 
additional data, these flavouring substances should be reconsidered using the Procedure. Subsequently, 
additional data might become necessary. Flavouring Group Evaluation 304 Revision 1
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavourings is regulated under Regulation (EC) No 1334/2008 of the European Parliament 
and Council of 16 December 2008
4 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and 
approval are required for flavouring substances. 
The Union list of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/2012
5. The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000
6. 
EFSA has evaluated five flavouring substances in the Flavouring Group Evaluation 304 (FGE.304). 
The Opinion was adopted on 27 September 2012. EFSA concluded that for two substances [FL-no: 
16.118 and 16.124] no appropriate NOAEL was available and additional data were required. 
The requested information on N-(2-(pyridine-2-yl)ethyl)-3-p-menthanecarboxamide [FL-no: 16.118] 
has now been submitted by the applicant. As regards substance [FL-no: 16.124], the Commission was 
informed that this substance is no longer supported by the applicant and its entry has been deleted 
from the Union List
7.  
The Commission asks EFSA to evaluate this new information and depending on the outcome proceed 
to the full evaluation of the flavouring substance. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests the European Food Safety Authority to carry out a safety 
assessment on the following substance N-(2-(pyridine-2-yl)ethyl)-3-p-menthanecarboxamide [FL-
no: 16.118] in accordance with Commission Regulation (EC) No 1565/2000. 
                                                      
4   Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34-50. 
5   Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of flavouring substances 
provided for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to 
Regulation (EC) No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) 
No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p, 1-161. 
6   Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8-16. 
7  Commission Regulation No 246/2014 of 13 March 2014 amending Annex I to Regulation (EC) No 1334/2008 of the 
European Parliament and of the Council as regards removal from the Union list of certain flavouring substances. OJ L 74,  
14.3.2014, p. 58-60. Flavouring Group Evaluation 304 Revision 1
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ASSESSMENT 
1.  History of the Evaluation of the Substances in FGE.304Rev1  
In FGE.304, the Panel evaluated a group of five carboxamides. The Panel concluded that for two 
candidate substances [FL-no: 16.118 and 16.124], no appropriate NOAEL was available and 
additional data were required. 
Since the publication of FGE.304, the Industry has informed (DG SANCO, 2013) that (1R,2S,5R)-N-
cyclopropyl-5-methyl-2-isopropyl cyclohexanecarboxamide [FL-no: 16.124] is no longer supported 
for use as flavouring substance in Europe. Accordingly the substance will not be considered any 
further in the present FGE. 
FGE  Opinion adopted  Link  No. of substances 
FGE.304  27 September 2012  http://www.efsa.europa.eu/en/efsajournal/pub/2903.htm 5 
FGE.304Rev1  3 July 2014    4 
 
The present revision of FGE.304, FGE.304Rev1, includes a re-evaluation of N-(2-(pyridine-2-
yl)ethyl)-3-p-menthanecarboxamide [FL-no: 16.118], as additional data, a 90-day dietary rat study has 
become available (Kirkpatrick, 2013). A search in the open literature did not provide any further 
relevant data on toxicity or metabolism for the substance [FL-no: 16.118]. 
2.  Presentation of the Substances in FGE.304Rev1 
2.1.  Description 
The present Flavouring Group Evaluation (FGE), using the Procedure as referred to in the 
Commission Regulation (EC) No 1565/2000
8 (The Procedure – shown in schematic form in Appendix 
A), deals with four substances, N-p-benzeneacetonitrile-menthanecarboxamide [FL-no: 16.117], N-(2-
(pyridine-2-yl)ethyl)-3-p-menthanecarboxamide [FL-no: 16.118], (1R,2S,5R)-N-(4-methoxyphenyl)-5-
methyl-2-(1-methylethyl)cyclohexanecarboxamide [FL-no: 16.123] and (2S,5R)-N-[4-(2-amino-2-
oxoethyl)phenyl]-5-methyl-2-(propan-2-yl)cyclohexanecarboxamide [FL-no: 16.125]. These 
flavouring substances (candidate substances) belong to chemical group 30, Annex I of Commission 
Regulation (EC) No 1565/2000. Three of the candidate substances [FL-no: 16.117, 16.123 and 16.125] 
are structurally related, the remaining [FL-no: 16.118] is not. 
The four flavouring substances under consideration, as well as their chemical Register names, 
FLAVIS- (FL-), Chemical Abstract Service- (CAS-), Council of Europe- (CoE-) and Flavor and 
Extract Manufactures Association- (FEMA-) numbers, structure and specifications, are listed in Table 
1.  
The outcome of the safety evaluation is summarised in Table 4. 
The Panel is aware that there are three amides in the Register, (N-ethyl-2-isopropyl-5-
methylcyclohexane carboxamide [FL-no: 16.013] (JECFA evaluated and considered in FGE.86), N1-
(2-methoxy-4-methylbenzyl)-N2-(2-(pyridin-2-yl)ethyl)oxalamide [FL-no: 16.101] and N-
[(ethoxycarbonyl)methyl]-p-menthane-3-carboxamide [FL-no: 16.111] (both JECFA evaluated and 
considered in FGE.94), showing partial structural similarity with the candidate substances in this FGE. 
However, these are not considered sufficiently structural similar and accordingly are not used as 
supporting substances for the candidate substances in the present FGE. 
                                                      
8 Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. Official Journal of the European Communities 
19.7.2000, L 180, 8-16. Flavouring Group Evaluation 304 Revision 1
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SUMMARY OF SPECIFICATION DATA 
Table 1:   Specification Summary for the Substances in FGE.304Rev1 
FL-no  EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a) 
Solubility in 
ethanol 
(b) 
Boiling point, °C 
(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 
(d) 
Spec.gravity 
(e) 
Specification comments 
16.117 
 
N-p-Benzeneacetonitrile-
menthanecarboxamide 
H
N
O
N 
4496 
 
852379-28-3 
Solid 
C19H26N2O 
298.43 
Insoluble 
Insoluble 
 
147-151.3 
IR NMR MS 
99 % 
n.a. 
n.a. 
 
In accordance with CASrn, 
Register name to be changed to 
(1R,3R,4S)-N-p-
Benzeneacetonitrile-
menthanecarboxamide. Min 
assay 99 % (sum of 
isomers:min 94 % (1R, 3R, 
4S)-N-p-Benzeneacetonitrile-
menthanecarboxamide and 0 - 
5 % (1R, 3S, 4S)-N-p-
Benzeneacetonitrile-
menthanecarboxamide. 
(Flavour Industry, 2012) 
16.118 
 
N-(2-(Pyridine-2-yl)ethyl)-
3-p-menthanecarboxamide 
H
N
O
N
 
4549 
 
847565-09-7 
Solid 
C18H28N2O 
288.43 
Soluble 
Soluble 
 
83 
IR NMR MS 
99 % 
n.a. 
n.a. 
 
In accordance with CASrn, 
Register name to be changed to 
(1R,2S,5R)-N-(2-(Pyridine-2-
yl)ethyl)-3-p-
menthanecarboxamide. 
16.123 
 
(1R,2S,5R)-N-(4-
Methoxyphenyl)-5-methyl-
2-(1-
methylethyl)cyclohexanecar
boxamide 
O
H
N
O  
4681 
 
68489-09-8 
Solid 
C18H27NO2 
289.42 
Insoluble 
Soluble 
 
177.7 
IR NMR MS 
95 % 
n.a. 
n.a. 
 
 
16.124 
 
(1R,2S,5R)-N-Cyclopropyl-
5-methyl-2-isopropyl 
cyclohexanecarboxamide 
H
N
O  
4693 
 
73435-61-7 
Solid 
C14H25NO 
223.19 
Soluble 
Soluble 
 
125 
IR NMR MS 
95 % 
n.a. 
0.23 
 
No longer supported by 
Industry (DG SANCO, 2013). Flavouring Group Evaluation 304 Revision 1
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Table 1:   Specification Summary for the Substances in FGE.304Rev1 
FL-no  EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a) 
Solubility in 
ethanol 
(b) 
Boiling point, °C 
(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 
(d) 
Spec.gravity 
(e) 
Specification comments 
16.125 
 
(2S,5R)-N-[4-(2-Amino-2-
oxoethyl)phenyl]-5-methyl-
2-(propan-2-
yl)cyclohexanecarboxamide 
H
N
O
NH2
O
4684 
 
1119711-29-3 
Solid 
C19H28N2O2 
316.2 
Sparingly 
soluble 
Soluble 
 
186-188 
IR NMR MS 
95 % 
n.a. 
0.4 
 
 
(a):  Solubility in water, if not otherwise stated. 
(b):  Solubility in 95 % ethanol, if not otherwise stated. 
(c):  At 1013.25 hPa, if not otherwise stated. 
(d):  At 20°C, if not otherwise stated. 
(e):  At 25°C, if not otherwise stated. 
n.a. not  applicable. 
 Flavouri
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2.2.  Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. Their 
flavour may be different, they may have different chemical properties resulting in possible variability 
in their absorption, distribution, metabolism, elimination and toxicity. Thus, information must be 
provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number etc.). 
The four candidate substances possess chiral centres. The substances have been presented with 
specification of the stereoisomeric composition. See Table 1. 
2.3.  Natural Occurrence in Food 
None of the candidate substances have been reported to occur naturally (TNO, 2014). 
3.  Specifications 
Purity criteria for the four substances have been provided by the Flavouring Industry (Flavour 
Industry, 2008a; Flavour Industry, 2008b; Flavour Industry, 2009; Flavour Industry, 2010) (Table 1). 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000
9, the 
information is adequate for the candidate substances. 
4.  Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties in 
the underreporting correction factor and to uncertainties in the percentage of consumers, the reliability 
of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
                                                      
9   Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. Official Journal of the European Communities 
19.7.2000, L 180, 8-16. Flavouring Group Evaluation 304 Revision 1
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assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported) (EC, 2000). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004). 
4.1.  Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999). These 
data are derived from surveys on annual production volumes in Europe. These surveys were conducted 
in 1995 by the International Organization of the Flavour Industry (IOFI), in which flavour 
manufacturers reported the total amount of each flavouring substance incorporated into food sold in 
the EU during the previous year (IOFI, 1995). The intake approach does not consider the possible 
natural occurrence in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population
10 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999). 
The total annual volume of production of the four candidate substances from use as flavouring 
substances in Europe is approximately 1700 kg (Flavour Industry, 2008a; Flavour Industry, 2008b; 
Flavour Industry, 2009; Flavour Industry, 2010).  
On the basis of the annual volumes of production reported for the four candidate substances, the daily 
per capita intakes for each of these flavourings have been estimated. The estimated daily per capita 
intakes of the substances from use as a flavouring substance will be: 120 µg/day for N-p-
benzeneacetonitrile-menthanecarboxamide [FL-no: 16.117], 61 µg/day for N-(2-(pyridine-2-yl)ethyl)-
3-p-menthanecarboxamide [FL-no: 16.118] and below 12 µg/day for the two remaining substances 
(Table 3). 
4.2.  Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). 
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
For the four candidate substances, information on food categories and normal and maximum use 
levels
11 were submitted by the Flavour Industry (Flavour Industry, 2008a; Flavour Industry, 2008b; 
Flavour Industry, 2009; Flavour Industry, 2010). The four candidate substances are used in flavoured 
food products divided into the food categories, outlined in Annex III of the Commission Regulation 
(EC) No 1565/2000 (EC, 2000), as shown in Table 2. For the present calculation of mTAMDI, the 
reported normal use levels were used. In the case where different use levels were reported for different 
food categories the highest reported normal use level was used. 
                                                      
10  EU figure 375 millions. This figure relates to EU population at the time for which production data are available, and is 
consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No production data are available 
for the enlarged EU. 
11   ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95
th percentile of reported 
usages (EFFA, 2002). Flavouring Group Evaluation 304 Revision 1
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Table 2:   Use of Candidate Substances in Various Food Categories  
Food 
category * 
Description Flavourings  used 
01.0  Dairy products, excluding products of category 2  Only [FL-no: 16.123]     
02.0  Fats and oils, and fat emulsions (type water-in-oil)  Only [FL-no: 16.123] 
03.0  Edible ices, including sherbet and sorbet  Only [FL-no: 16.123] 
04.1  Processed fruits  Only [FL-no: 16.123 and 
16.125] 
04.2  Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and 
legumes), and nuts & seeds 
Only [FL-no: 16.125] 
05.0  Confectionery All 
06.0  Cereals and cereal products, incl. flours & starches from roots & tubers, 
pulses & legumes, excluding bakery 
Only [FL-no: 16.123] 
07.0  Bakery wares  Only [FL-no: 16.123] 
08.0  Meat and meat products, including poultry and game  None 
09.0  Fish and fish products, including molluscs, crustaceans and echinoderms   None 
10.0  Eggs and egg products  Only [FL-no: 16.123] 
11.0  Sweeteners, including honey  Only [FL-no: 16.123] 
12.0  Salts, spices, soups, sauces, salads, protein products etc.  Only [FL-no: 16.123] 
13.0  Foodstuffs intended for particular nutritional uses.  None 
14.1  Non-alcoholic ("soft") beverages, excl. dairy products  All 
14.2  Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts  Only [FL-no: 16.123] 
15.0  Ready-to-eat savouries  None 
16.0  Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could 
not be placed in categories 1 – 15 
None 
* All candidate substances are also used in chewing gum 
 
According to the Flavour Industry the normal use levels for the four candidate substances are in the 
range of 0.1 - 150 mg/kg food, and the maximum use levels are in the range of 1 - 300 mg/kg (Flavour 
Industry, 2008a; Flavour Industry, 2008b; Flavour Industry, 2009; Flavour Industry, 2010). 
All four candidate substances are also used in chewing gum, which is not covered by any of the above 
food categories. Normal/maximum use levels for chewing gum are 200/800 mg/kg for [FL-no: 
16.117], 100/300 mg/kg for [FL-no: 16.118], 30/300 mg/kg for [FL-no: 16.123] and 400/800 mg/kg 
for [FL-no: 16.125]. 
For the substances [FL-no: 16.117 and 16.118], the Industry has informed that only 10 % of the 
amount added is released from the chewing gum (Sostmann, 2006). For [FL-no: 16.125] there is a 
release of 10.5 % (Flavour Industry, 2009). For the remaining substance [FL-no: 16.123] there is no 
information on % release. Taking these % releases and an intake estimate of 2 g chewing gum/day into 
consideration, the mTAMDI of the candidate substances is calculated based on the 16 food categories 
and the use of chewing gum. These figures are presented in Tables B.2.3 and 3. 
The mTAMDI values for the four candidate substances from structural class III range from 150 to 
7800 µg/person/day. 
For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 7 and Appendix B. 
5.  Absorption, Distribution, Metabolism and Elimination  
The hydrolysis of [
14C]-N-p-benzenenitrile-menthanecarboxamide [FL-no: 16.117] was studied in rat 
and human hepatic microsomes (Sipes and Kong, 2012). As a positive control the hydrolysis of 
isoeugenol acetate, a known substrate of carboxyl esterase, was used. The results show that Flavouring Group Evaluation 304 Revision 1
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metabolically active male rat or human microsomes did not hydrolyse N-p-benzenenitrile-
menthanecarboxamide [FL-no: 16.117]. 
The possible release of cyanide from the candidate substance N-p-benzenenitrile-
menthanecarboxamide [FL-no: 16.117] during metabolism was studied in rat and human hepatocytes. 
Incubations of up to 250 µM of the candidate substance with human or rat hepatocytes for up to four 
hours only resulted in release of low amounts, if any, of cyanide. Proper positive control incubations 
with benzyl nitrile and sodium cyanide were included in the study (Wolff and Skibbe, 2007). 
Specific information regarding absorption, distribution, metabolism and excretion is not available for 
the remaining three candidate substances. The candidate aromatic amides are anticipated to being 
absorbed from the gastrointestinal tract like other aromatic amides. Aromatic amides are expected to 
be metabolised to polar metabolites which are eliminated in the urine or bile (James, 1974; Schwen, 
1982).  
The hydrolysis of a substance with partial structure similarity to [FL-no: 16.117] from FGE.94Rev1, 
N-[(ethoxycarbonyl)methyl]-p-menthane-3-carboxamide [FL-no: 16.111], was studied in artificial 
pancreatic juice and rat liver homogenate (Poet et al., 2005). Based on the disappearance of the 
employed substrate, [FL-no: 16.111] was hydrolysed in artificial pancreatic juice with a half-life of 43 
± 14.7 min. and a first order rate constant (K) of 1.06 ± 0.426 hour
-1. In 20 fold-diluted liver 
homogenate the disappearance of [FL-no: 16.111] was considerably faster (half-life: 0.802 ±0.191 
min.). However, the potential hydrolysis products, p-menthane-3-carboxylic acid, glycine ethylester 
and glycine, were only detected at trace levels. This indicates that the disappearance of [FL-no: 
16.111] under the employed in vitro-conditions is due to the hydrolysis of the ethyl ester bond rather 
than the hydrolysis of the amide bond. 
Data on the candidate substance [FL-no: 16.117) and another carboxamide [FL-no: 16.111]  do not 
demonstrate hydrolysis of the amide bond under the in vitro conditions applied. Owing to the lack of 
further data, the candidate substances cannot be anticipated to be metabolised to innocuous products. 
For more detailed information, see Appendix C. 
6.  Application of the Procedure for the Safety Evaluation of Flavouring 
Substances  
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 7. 
For the safety evaluation of the four candidate substances from chemical group 30 the Procedure as 
outlined in Appendix A was applied, based on the MSDI approach. The stepwise evaluations of the 
substances are summarised in Table 4. 
Step 1 
All four candidate substances are classified into structural class III according to the decision tree 
approach presented by Cramer et al. (Cramer et al., 1978). 
Step 2 
Step 2 requires consideration of the metabolism of the candidate substances. The four candidate 
substances [FL-no: 16.117, 16.118, 16.123 and 16.125], cannot be anticipated to be metabolised to 
innocuous products and thus the evaluation proceeds via the B-side of the Procedure scheme. Flavouring Group Evaluation 304 Revision 1
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Step B3 
The four candidate substances are allocated to structural class III. Three of the candidate substances 
[FL-no: 16.118, 16.123 and 16.125] have estimated European daily per capita intakes (MSDI) ranging 
from 6.1 to 61 µg (Table 4). These intakes are below the threshold of concern of 90 µg/person/day for 
structural class III. Accordingly, they proceed to step B4 of the Procedure. 
One candidate substance N-p-benzeneacetonitrile-menthanecarboxamide [FL-no: 16.117] has an 
estimated European daily per capita intake (MSDI) of 120 µg (Table 4), which is above the threshold 
of concern of 90 µg/person/day for structural class III. Therefore, data must be available on the 
substance or closely related substances to perform a safety evaluation. On the basis of a 90-day study 
in rats exposed to N-p-benzeneacetonitrile-menthanecarboxamide [FL-no: 16.117] in the diet, a No 
Observed Adverse Effect Level (NOAEL) of 100 mg/kg body weight (bw)/day was identified. The 
MSDI value of 120 µg/capita/day is equivalent to 2 µg/kg bw/day, at a body weight of 60 kg. Thus, 
the margin of safety is 50000. 
Based on results of the safety evaluation through the Procedure, N-p-benzeneacetonitrile-
menthanecarboxamide [FL-no: 16.117] is not anticipated to pose a safety concern when used as 
flavouring substances at the estimated levels of intake, based on the MSDI approach. 
Step B4 
A NOAEL of 100 mg/kg bw/day was reported for N-p-benzeneacetonitrile-menthanecarboxamide 
[FL-no: 16.117]. This substance is structurally related to the two substances [FL-no: 16.123 and 
16.125]. The combined estimated daily per capita intake of 18 µg for the two candidate substances 
corresponds to 0.3 µg/kg bw/day, at a body weight of 60 kg. Thus, a margin of safety of 3.3 x 10
5 can 
be calculated. Therefore, the two substances [FL-no: 16.123 and 16.125] are not anticipated to pose a 
safety concern when used as flavouring substances at the estimated levels of intake, based on the 
MSDI approach. 
For the remaining candidate substance N-(2-(pyridine-2-yl)ethyl)-3-p-menthanecarboxamide [FL-no: 
16.118] an NOAEL of 5 mg/kg bw/day was derived from a 90-day study in rats. Based on the MSDI 
intake level of 61 μg/capita/day this results in a margin of safety of 5000. 
Therefore, based on results of the safety evaluation following the Procedure, the Panel concludes that 
the substances [FL-no: 16.117, 16.118, 16.123 and 16.125] do not pose a safety concern when used as 
flavouring substances at the estimated level of intake, based on the MSDI approach. 
7.  Comparison of the Intake Estimations Based on the MSDI Approach and the 
mTAMDI Approach 
The mTAMDI intakes for the four candidate substances in structural class III range from 150 to 7800 
µg/person/day, which all are above the threshold of concern of 90 µg/person/day.  
Accordingly, further information is required for all candidate substances. This would include more 
reliable intake data and then, if required, additional toxicological data. 
For comparison of the intake estimates based on the MSDI approach and the mTAMDI approach, see 
Table 3.  
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Table 3:   Estimated Intakes Based on the MSDI Approach and the mTAMDI approach 
FL-no EU  Register  name  MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of 
concern 
(µg/person/day) 
16.117  N-p-Benzeneacetonitrile-
menthanecarboxamide 
120 4400  Class  III  90 
16.118  N-(2-(Pyridine-2-yl)ethyl)-3-p-
menthanecarboxamide 
61 2500  Class  III  90 
16.123 (1R,2S,5R)-N-(4-
Methoxyphenyl)-5-methyl-2-(1-
methylethyl)cyclohexanecarbox
amide 
12 150  Class  III  90 
16.125 (2S,5R)-N-[4-(2-Amino-2-
oxoethyl)phenyl]-5-methyl-2-
(propan-2-
yl)cyclohexanecarboxamide 
6.1 7800  Class  III  90 
8.  Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances. 
On the basis of the reported annual production volumes in Europe (Flavour Industry, 2008a; Flavour 
Industry, 2008b; Flavour Industry, 2009; Flavour Industry, 2010), the combined estimated daily per 
capita intake as flavourings of the three structurally similar candidate substances [FL-no: 16.117, 
16.123 and 16.125] assigned to class III is 138 µg, which exceeds the threshold of concern for a 
substance belonging to structural class III of 90 µg/person/day. 
The combined estimated intake of 138 µg/capita/day corresponds to 2.3 µg/kg bw/day, which is more 
than 40000 fold lower than the NOAEL of 100 mg/kg bw/day for N-p-benzeneacetonitrile-
menthanecarboxamide [FL-no: 16.117] (See Section 9.2). 
9.  Toxicity 
9.1.  Acute Toxicity 
Data are available for three candidate substances [FL-no: 16.117, 16.118 and 16.123]. Oral LD50 
values are in the range of 300 to more than 2000 mg/kg bw in rats.  
Acute toxicity data are summarised in Table 5. 
9.2.  Subacute, Subchronic, Chronic and Carcinogenicity Studies 
A 90-day oral dosing study in rats is available for the candidate substance [FL-no: 16.117] and a 90-
day as well as two 28-day oral dosing studies in rats are available for the candidate substance [FL-no: 
16.118]. 
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90-day oral toxicity study with N-p-benzeneacetonitrile-menthanecarboxamide [FL-no: 16.117] 
Groups of male and female rats (N = 10 or 15, control and highest dose of which five were in recovery 
groups for additional 28 days) were administered N-p-benzeneacetonitrile-menthanecarboxamide [FL-
no: 16.117] in the diet at concentration corresponding to doses of 0, 100, 300 and 1000 mg/kg bw/day 
for 90 days. The study was conducted in accordance with OECD Guidelines 408 (Eapen, 2007). 
Significant effects ascribed to the exposure were a slight increase in methemoglobin in females dosed 
1000 mg/kg bw/day, increased cholesterol and potassium in males dosed 300 and 1000 mg/kg bw/day, 
which were normalised after the recovery period. Females dosed with 100, 300 and 1000 mg/kg 
bw/day had reduced alanin transaminase (ALAT), females dosed with 100 and 1000 mg/kg bw had 
reduced aspartate transaminase (ASAT). However, decrease in ASAT and ALAT is of no 
toxicological relevance. Females dosed with 300 and 1000 mg/kg bw/day had reduced triglyceride. 
These effects were normalised after the recovery period. No dose related effects were detected on 
urine analysis or on macroscopic examination. Significant increased liver weight relative to body 
weight was observed in both males and females dosed 300 and 1000 mg/kg bw/day. There were no 
histological substance-related changes in any tissue, including the thyroids in the rats examined after 
the primary and recovery necropsy (see studies with [FL no: 16.118] described below (Eapen, 2007). 
A NOAEL of 100 mg/kg bw/day could be derived.  
28-day oral toxicity studies with N-(2-(pyridine-2-yl)ethyl)-3-p-menthanecarboxamide [FL-no: 
16.118] 
Groups of male and female Sprague-Dawley rats (N = 5) were administered N-(2-(pyridine-2-
yl)ethyl)-3-p-menthanecarboxamide [FL-no: 16.118] in the diet at concentration corresponding to 
doses of 0, 100, 300 and 1000 mg/kg bw/day for 28 days (Chase, 2008). Treatment related changes 
were detected in the liver and thyroid at all dose levels and due to the presence of fatty vacuolation in 
the liver, a NOAEL could not be established. 
In another  study, groups of male and female Sprague-Dawley rats (N = 8) were administered N-(2-
(pyridine-2-yl)ethyl)-3-p-menthanecarboxamide [FL-no: 16.118] in the diet at concentrations 
corresponding to doses of 0, 10, 50 and 300 mg/kg bw/day for 28 days (Eapen, 2008).  
Significant effects ascribed to the exposure were higher albumin and globin, lower triglyceride in 
males in the 300 mg/kg bw/day group, higher cholesterol in males and females in the 300 mg/kg 
bw/day group, higher T3 in males and females in 300 mg/kg group and in females in the 50 mg/kg 
bw/day group, and increased absolute and relative liver weight in both males and females was found in 
the 300 mg/kg bw/day group. Follicular cell hypertrophy of the thyroid gland were observed in four 
females (300 mg/kg bw/day), seven males (300 mg/kg bw/day), two males (50 mg/kg bw/day), one 
male (10 mg/kg bw/day) and 1 male (0 mg/kg bw/day); the significance of these findings was not 
reported (Eapen, 2008). A NOAEL of 10 mg/kg bw/day could be derived, but owing to the short 
duration of this study, this NOAEL cannot be used for safety assessment of this and structurally 
related substances.  
90-day oral toxicity study with N-(2-(pyridine-2-yl)ethyl)-3-p-menthanecarboxamide [FL-no: 16.118] 
This study (Kirkpatrick, 2013) was performed by the same institute as the 28-day study of Eapen 
(Eapen, 2008). Groups of male and female Sprague Dawley rats (N = 10 at the lower and middle dose, 
or N = 15 at control and highest dose, of which five were in recovery groups for an additional 28 days 
period) were administered N-(2-(pyridine-2-yl)ethyl)-3-p-menthanecarboxamide [FL-no: 16.118] in 
the diet at concentration corresponding to doses of 0, 5, 20 and 50 mg/kg bw/day for 90 days. The rats 
were caged individually. The purity of [FL-no: 16.118] was 99,7 %; the diet was prepared fresh once 
every week and the candidate substance was shown to be stable during that period. This GLP study 
was conducted in accordance with OECD Guidelines 408.  Flavouring Group Evaluation 304 Revision 1
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The objectives of this study were to evaluate the potential toxic effects of [FL-no: 16.118] when 
administered via the diet to rats for 90 consecutive days and to assess recovery from such effects. This 
study included evaluation of potential neurotoxicity by functional observational battery (FOB) and 
motor activity (MA) assessment: a range of observations (“Home cage”, handling, open field, sensory, 
neuromuscular and physiological observations and measuring ambulatory activity) including some 
challenge-tests. 
All animals were observed twice daily for mortality and moribundity. Clinical examinations were 
performed daily, and detailed physical examinations were performed weekly. Individual body weights 
and individual food consumption were recorded weekly. FOB and MA data were recorded for all 
animals during study week 12. Ophthalmic examinations were performed at the beginning of the study 
and on day 86 (all animals). Clinical pathology parameters (hematology, coagulation, serum 
chemistry, thyroid parameters and urinalysis) were analysed for all animals assigned to the primary 
(study week 13) and recovery (study week 17) necropsies. Complete necropsies were conducted on all 
animals, and selected organs were weighed. Selected tissues were examined microscopically from all 
animals found dead, euthanized in extremis, and in the control and 50 mg/kg bw/day groups at the 
primary necropsy. Gross lesions and the thyroid glands (males and females) and the liver (females 
only) were also examined microscopically from animals in the 5 and 20 mg/kg bw/day groups at the 
primary necropsy. In addition, the liver (females only) and the thyroid glands (males and females) 
were examined microscopically from all surviving animals in the control and 50 mg/kg bw/day groups 
at the recovery necropsy. 
A single treated (50 mg/kg bw/day) female was found dead on study day 63; however, the cause of 
death in this animal could not be determined and was considered not test article-related by the authors.  
There were no clinical, ophthalmic, or macroscopic observations or effects on body weights, food 
consumption, FOB parameters, MA patterns, serum chemistry parameters, or urinalysis parameters.  
Test article-related lower mean hemoglobin, mean corpuscular volume (MCV) and mean corpuscular 
hemoglobin (MCH) values were noted in the 50 mg/kg bw/day group males at the primary necropsy. 
The effect was minimal and considered not adverse. Values at the recovery necropsy indicated 
reversibility.  
Test article-related higher liver weights were noted for the 50 mg/kg bw/day group males at the 
primary necropsy; however, no histological changes were found. The effect was reversible as observed 
in the recovery group.  In females mild centrilobular hepatocellular hypertrophy was noted in the liver 
of some 20 (n = 3) and 50 (n = 2) mg/kg/day group (n = 10 in each group) females at the primary and 
one in the 50 mg/kg bw/day recovery Group (n = 5) necropsies; it was considered a non-adverse 
adaptive response by the authors of the study. Indeed, blood clinical chemistry did not show any signs 
of liver toxicity. 
A dose-related increase in thyroid-stimulating hormone (TSH) values of 50 % at the highest dose was 
noted in both males and females at the primary necropsy; values at the recovery necropsy indicated 
reversibility. The levels of the thyroid hormones T3, T4 and rT3
12 were also measured. For rT3 there 
was no effect in any treatment group. However, T4 (thyroxine) showed a dose-related increase (by 
max. 40 %) in females, but no change at all in males; again in the recovery group the effect had 
disappeared, indicating reversibility. For T3 only the highest dose showed a 25 % increase in both 
sexes similarly, which seemed reversible. 
By histopathology a dose-related decreased amount of colloid (scored as minimal to moderate) as well 
as follicular cell hypertrophy (scored as minimal to moderate) were noted in the thyroid gland of the 5, 
20 and 50 mg/kg bw/day males and 5 and 50 mg/kg bw/day females. At the 5 mg/kg bw/day only 
minimal effects were observed in four and one rats of the male and female group, respectively. Given 
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the ability of  mild to moderate thyroid follicular hypertrophy to progress to neoplasia in rats, mild and 
moderate changes could be considered to be adverse. The authors, however, considered these thyroid 
gland effects secondary to hepatic microsomal enzyme induction, but did not provide data to support 
this. Indeed, induction of the UDP glucuronyltransferase (UGT) that conjugates T4 in the liver would 
give rise to a compensatory increase in TSH in the rat. In humans, T4 is metabolised by sulphation, 
and therefore the observed effect in the rat may be considered irrelevant for humans, as extensively 
discussed by (Capen, 2008). However, data on UGT induction have not been  provided  by the 
authors.  
Mild to moderate thyroid follicular hypertrophy, as observed in the 20 and 50 mg/kg bw/day groups, 
was considered adverse. This finding might be considered to be of negligible toxicological relevance 
to humans (Capen, 2008); however, the authors did not prove the proposed mechanism by 
measurement of UGT activity in the liver of treated animals. The Panel considered 5 mg/kg bw/day as 
the No-Observed-Adverse-Effect Level (NOAEL) when [FL-no: 16.118] was administered in the diet 
to rats over a period of 90 days, given the minimal thyroid changes in this dose group.  
Repeated dose toxicity data are summarised in Table 6. 
9.3.  Developmental / Reproductive Toxicity Studies 
No data are available on developmental or reproductive toxicity for the candidate substance or for 
supporting substances. 
9.4.  Genotoxicity Studies 
With three candidate substances, N-p-benzeneacetonitrile-menthanecarboxamide [FL-no: 16.117, N-
(2-(pyridine-2-yl)ethyl)-3-p-menthanecarboxamide [FL-no: 16.118] and (1R,2S,5R)-N-(4-
methoxyphenyl)-5-methyl-2-(1-methylethyl)cyclohexanecarboxamide [FL-no: 16.123], valid bacterial 
mutagenicity studies have been performed in absence and in presence of metabolic activation up to 
sufficiently high concentrations. These studies did not provide indications for genotoxic activity 
(Sokolowski, 2004; May, 2007; Bowles, 2008).  
With the candidate substance N-p-benzeneacetonitrile-menthanecarboxamide [FL-no: 16.117] also a 
chromosomal aberration test in human lymphocytes has been carried out, which provided no 
indication of clastogenicity (Bowen, 2007), but this test was of limited validity as the negative result in 
presence of metabolic activation was not confirmed in a second test. However, in an additional study 
with this substance, again a negative result in presence of metabolic activation was obtained (Woods, 
2008), so that overall the conclusion that [FL-no: 16.117] did not show clastogenic potential in vitro 
could be drawn. An in vivo bone marrow micronucleus assay in the mouse did not indicate a 
clastogenic potential for [FL-no: 16.117] either, but that result was of limited relevance due to absence 
of target organ toxicity (Pritchard, 2011). 
With substance [FL-no: 16.118] at concentrations ranging from 100 to 300 µg/ml, a negative result 
was obtained in a human lymphocyte test for chromosomal aberrations after 3 hours of exposure in 
presence of metabolic activation. A repeat assay to confirm this negative result was not carried out. A 
negative result was also obtained with this substance at concentrations ranging from 260 to 300 µg/ml 
after 3 hours of exposure in absence of metabolic activation, but in the repeat assay to confirm this 
negative result with the substance at concentrations ranging from 25 - 160 µg/ml, an equivocal result 
(4.5 % cells with chromatid breaks at the highest level tested (160 µg/ml) vs. 1 % in the non-exposed 
cells) was obtained. This increased incidence was outside the historical control range, but it was not 
statistically significant in comparison with the concurrent control (Mason, 2007). Additional scoring 
of hundred extra metaphases from the Mason (2007) study was performed by Pritchard (Pritchard, 
2011), to provide more robust data from this study. The result from additional scoring showed no 
increase in the percentage cells with aberrations excluding gaps. Furthermore, the aberration 
frequencies fell within the historical control range. Flavouring Group Evaluation 304 Revision 1
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Conclusion on genotoxicity:  
The data available do not give rise to safety concern with respect to genotoxicity for the candidate 
substances. 
Genotoxicity data are summarised in Tables 7 and 8. 
CONCLUSIONS  
The present Flavouring Group Evaluation deals with four carboxamides. Since the publication of the 
previous version, FGE.304, one of the original five candidate substances [FL-no: 16.124], for which 
additional data were required, is no longer supported by Industry for use as flavouring substance in 
Europe and will therefore not be considered any further. This revision of FGE.304, FGE.304Rev1, 
therefore only deals with four candidate substances N-p-benzeneacetonitrile-menthanecarboxamide 
[FL-no: 16.117], N-(2-(pyridine-2-yl)ethyl)-3-p-menthanecarboxamide [FL-no: 16.118], (1R,2S,5R)-
N-(4-methoxyphenyl)-5-methyl-2-(1-methylethyl)cyclohexanecarboxamide [FL-no: 16.123] and 
(2S,5R)-N-[4-(2-amino-2-oxoethyl)phenyl]-5-methyl-2-(propan-2-yl)cyclohexanecarboxamide [FL-
no: 16.125]. 
Further, the present revision of FGE.304, FGE.304Rev1, includes the assessment of new toxicity data 
on  N-(2-(pyridine-2-yl)ethyl)-3-p-menthanecarboxamide [FL-no: 16.118] for which additional data 
were required. The four flavouring substances possess chiral centres. All substances have been 
presented with specification of the stereoisomeric composition. 
All candidate substances were assigned to structural class III, according to the decision tree approach 
presented by Cramer et al., 1978. 
None of the candidate substances have been reported to occur naturally. 
Genotoxicity data are available for three of the substances. The Panel concluded that the data available 
do not give rise to safety concern with respect to genotoxicity for any of the candidate substances.  
On the basis of the available data, the hydrolysis of the candidate substances cannot be excluded. 
However, owing to the lack of further data, the candidate substances cannot be anticipated to be 
metabolised to innocuous products. 
According to the default MSDI approach, the three flavouring substances [FL-no: 16.118, 16.123 and 
16.125] in this group have intakes in Europe from 6.1 to 61 µg/capita/day, which are below the 
threshold of concern value for structural class III of 90 µg/person/day. For one substance [FL-no: 
16.117] the intake of 120 µg/capita/day is above the threshold of concern. However, an adequate 
NOAEL of 100 mg/kg bw/day exists from a 90-day study with this candidate substance [FL-no: 
16.117], which provides a margin of safety of 50000. This substance is structurally related to the two 
substances [FL-no: 16.123 and 16.125] for which a margin of safety of 3.3 x 10
5, based on the 
combined estimated daily per capita intake, can be calculated. For the remaining candidate substance 
[FL-no: 16.118] a 90-day study has become available and a NOAEL to provide adequate margin of 
safety of 5000 is derived. Therefore, the four substances [FL-no: 16.117, 16.118, 16.123 and 16.125] 
are not anticipated to pose a safety concern when used as flavouring substances at the estimated levels 
of intake, based on the MSDI approach. 
In order to determine whether the conclusion for the four candidate substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate specifications 
including complete purity criteria and identity tests for the materials of commerce have been provided 
for all the flavouring substances. Thus, the final evaluation of the materials of commerce can be 
performed for all four substances. Flavouring Group Evaluation 304 Revision 1
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In conclusion, for all flavouring substance [FL-no: 16.117, 16.118, 16.123 and 16.125], the Panel 
considered that they would present no safety concern at the estimated levels of intake estimated on the 
basis of the MSDI approach. 
However, when the estimated intakes were based on the mTAMDI approach, they ranged from 210 to 
7900 µg/person/day for the four candidate substances from structural class III, which are above the 
threshold of concern for structural class III of 90 µg/person/day. Therefore more reliable exposure data 
are required for these substances [FL-no: 16.117, 16.118, 16.123 and 16.125]. On the basis of such 
additional data, these flavouring substances should be reconsidered using the Procedure. Subsequently, 
additional data might become necessary. Flavouring Group Evaluation 304 Revision 1
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SUMMARY OF SAFETY EVALUATION 
Table 4:   Summary of Safety Evaluation Applying the Procedure 
FL-no  EU Register name  Structural formula  MSDI 
(a) 
(μg/capita/day) 
Class 
(b) 
Evaluation procedure 
path 
(c) 
Outcome on the 
named compound 
[
(d) or 
(e)] 
Outcome on 
the material of 
commerce [
(f) , 
(g) or 
(h)] 
Evaluation remarks 
16.117 
 
N-p-Benzeneacetonitrile-
menthanecarboxamide 
H
N
O
N 
120 
 
Class III 
B3: Intake above 
threshold 
d f   
16.118 
 
N-(2-(Pyridine-2-yl)ethyl)-
3-p-menthanecarboxamide 
H
N
O
N
 
61 
 
Class III 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f   
16.123 
 
(1R,2S,5R)-N-(4-
Methoxyphenyl)-5-methyl-
2-(1-
methylethyl)cyclohexanecar
boxamide 
O
H
N
O  
12 
 
Class III 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f   
16.124 
 
(1R,2S,5R)-N-Cyclopropyl-
5-methyl-2-isopropyl 
cyclohexanecarboxamide 
H
N
O  
6.1 
 
Class III 
B3: Intake below 
threshold, B4: No 
adequate NOAEL 
Additional data 
required 
  No longer supported by 
Industry (DG SANCO, 
2013). 
16.125 
 
(2S,5R)-N-[4-(2-Amino-2-
oxoethyl)phenyl]-5-methyl-
2-(propan-2-
yl)cyclohexanecarboxamide 
H
N
O
NH2
O
6.1 
 
Class III 
B3: Intake below 
threshold, B4: Adequate 
NOAEL exists 
d f   
(a):  EU MSDI: Amount added to food as flavour in (kg / year) x 10
9 / (0.1 x population in Europe (= 375 x 10
6) x 0.6 x 365)  =  µg/capita/day. 
(b):  Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. Flavouring Group Evaluation 304 Revision 1
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(c):  Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
(d):  No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e):  Data must be available on the substance or closely related substances to perform a safety evaluation. 
(f):  No safety concern at the estimated level of intake of the material of commerce meeting the specification requirement (based on intake calculated by the MSDI approach). 
(g): Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or 
information on stereoisomerism. 
(h):  No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
 
 TOXICITY DATA 
Table 5:   Acute Toxicity 
Chemical Name [FL-no]   Species   Sex   Route   LD50 
(mg/kg bw)  
Reference   Comments 
N-p-benzeneacetonitrile-
menthanecarboxamide [16.117] 
Rat M,F  Oral  >2000  (Mallory,  2004)   
N-(2-(Pyridine-2-yl)ethyl)-3-p-
menthanecarboxamide [16.118] 
Rat F  Oral 
 
Between 300 and 
2000 
(Groom, 2007)   
(1R,2S,5R)-N-(4-Methoxyphenyl)-5-
methyl-2-(1-
methylethyl)cyclohexanecarboxamide 
[16.123] 
Rat F  Oral  >2000  (Bradshaw,  2008)   
 
Table 6:   Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no]   Species; Sex 
No./Group 
Route   Dose levels  Duration  NOAEL 
(mg/kg bw/day) 
Reference Comments 
N-p-benzeneacetonitrile-
menthanecarboxamide 
[16.117] 
Rat; M,F 
10 
Diet  100, 300 and 
1000 mg/kg 
bw/day 
90 days  100  (Eapen, 2007)  OECD Guideline study 
(408). 
N-(2-(Pyridine-2-yl)ethyl)-
3-p-menthanecarboxamide 
[16.118] 
Rat; M,F 
5 
Diet  100, 300 and 
1000 mg/kg 
bw/day 
28 days    (Chase, 2008)   
Rat; M,F 
8 
Diet  10, 50 and 300 
mg/kg bw/day 
28 days  10  (Eapen, 2008)   
Rat; M,F 
10 
Diet   5, 20 and 50 
mg/kg bw/day
90 days  5  (Kirkpatrick, 2013)  OECD Guideline study 
(408).
 Flavouring Group Evaluation 304 Revision 1
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GENOTOXICITY DATA 
Table 7:   Genotoxicity (in vitro) 
Chemical Name [FL-no]   Test System  Test Object   Concentration  Result   Reference   Comments 
N-p-benzeneacetonitrile-
menthanecarboxamide [16.117] 
Reverse mutation  S. typhimurium,TA98, 
TA100, TA1535, TA1537 
and 
E. coli WP2 uvrA 
3 - 5000 µg/plate Negative
(a) (Sokolowski, 2004)  Valid study. 
Chromosomal aberration  Human lymphocytes  373 - 2984 µg/ml Negative  (Bowen,  2007) Valid  together  with 
the study by 
Woods, 2008. 
Chromosomal aberration  Human lymphocytes  367 - 2938 µg/ml  Negative
(b) (Woods, 2008)  Confirmatory test 
for Bowen, 2007. 
N-(2-(Pyridine-2-yl)ethyl)-3-p-
menthanecarboxamide [16.118] 
Reverse mutation  S. typhimurium,TA98, 
TA100, TA1535, TA1537 
and 
E. coli WP2 uvrA 
5 - 5000 µg/plate Negative
(a) (May,  2007)  Valid  study. 
Chromosomal aberration  Human lymphocytes  25 - 300 µg/ml  Equivocal
(c)
Negative
(c) 
(Mason, 2007) 
(Pritchard, 2011) 
 
Valid study. 
Chromosomal aberration  Human lymphocytes  100 - 300 µg/ml  Negative
(b)  (Mason, 2007)  Limited relevance 
(no repeat study). 
(1R,2S,5R)-N-(4-Methoxyphenyl)-5-
methyl-2-(1-
methylethyl)cyclohexanecarboxamide 
[16.123] 
Reverse mutation  S. typhimurium,TA98, 
TA100, TA102, TA1535 
and TA1537 
 
50 - 5000 µg/plate  Negative
(a) (Bowles,  2008)  Valid  study. 
(a):  With and without metabolic activation. 
(b): With  metabolic  activation. 
(c): Without  metabolic  activation. 
 
Table 8:   Genotoxicity (in vivo) 
Chemical Name [FL-no]   Test System  Test Object  Route  Dose  Result   Reference   Comments 
N-p-benzeneacetonitrile-
menthanecarboxamide [16.117] 
Micronucleus 
induction 
Mice Gavage  500  -  2000  mg/kg 
bw/day 
Negative (Pritchard, 
2007) 
Of limited relevance due to absence 
of target tissue toxicity Flavouring Group Evaluation 304 Revision 1
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APPENDIX A: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000), named the "Procedure", is shown in schematic 
form in Figure A.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed 
on 2 December 1999 (SCF, 1999), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44
th, 46
th and 49
th meetings (JECFA, 1995; JECFA, 
1996; JECFA, 1997; JECFA, 1999). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 µg/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
•  can the flavourings be predicted to be metabolised to innocuous products
13 (Step 2)?  
•  do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
•  are the flavourings or their metabolites endogenous
14 (Step A4)?  
•  does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions. 
 
                                                      
13 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the estimated intakes of  
the flavouring agent” (JECFA, 1997). 
14 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or conjugated;  
hormones and other substances with biochemical or physiological regulatory functions are not included (JECFA, 1997). Flavouring Group Evaluation 304 Revision 1
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Decision tree structural class
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Data must be available on the 
substance or closely related 
substances to perform a safety 
evaluation
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
  Substance would not be   
expected to be of safety concern
Is the substance or are its metabolites endogenous? 
Additional data required
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3.
Step B4.
 Yes  No
 Yes 
 No 
No 
No
Yes
No
Yes
Yes 
Yes 
 No
Figure A.1 Procedure for Safety Evaluation of Chemically Defined Flavouring SubstancesFlavouring Group Evaluation 304 Revision 1
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APPENDIX B: USE LEVELS / MTAMDI 
B.1  Normal and Maximum Use Levels 
For each of the 18 Food categories (Table B.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000). According to the 
Industry the ”normal use” is defined as the average of reported usages and ”maximum use” is defined 
as the 95
th percentile of reported usages (EFFA, 2002). The normal and maximum use levels in 
different food categories have been extrapolated from figures derived from 12 model flavouring 
substances (EFFA, 2004). 
Table B.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000). 
Food category  Description 
01.0  Dairy products, excluding products of category 02.0 
02.0  Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible  ices,  including sherbet and sorbet 
04.1 Processed  fruit 
04.2  Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds
05.0 Confectionery 
06.0  Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding 
bakery 
07.0 Bakery  wares 
08.0  Meat and meat products, including poultry and game
09.0  Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0  Eggs and egg products 
11.0 Sweeteners,  including  honey 
12.0  Salts, spices, soups, sauces, salads, protein products, etc. 
13.0  Foodstuffs intended for particular nutritional uses 
14.1  Non-alcoholic ("soft") beverages, excl. dairy products 
14.2  Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat  savouries 
16.0  Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 
01.0 - 15.0 
 
The “normal and maximum use levels” are provided by Industry for the four candidate substances in 
the present flavouring group (Table B.1.2). 
B.2  mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may 
consume the amount of flavourable foods and beverages listed in Table B.2.1. These consumption 
estimates are then multiplied by the reported use levels in the different food categories and summed 
up. 
Table B.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed 
per person per day (SCF, 1995). 
Class of product category  Intake estimate (g/day) 
Beverages (non-alcoholic)  324.0 
Foods 133.4 
Exception a: Candy, confectionery  27.0 
Exception b: Condiments, seasonings  20.0 
Exception c: Alcoholic beverages  20.0
Exception d: Soups, savouries  20.0 Flavouring Group Evaluation 304 Revision 1
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Table B.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed 
per person per day (SCF, 1995). 
Class of product category  Intake estimate (g/day) 
Exception e: Others, e.g. chewing gum  e.g. 2.0 (chewing gum) Flavouring Group Evaluation 304 Revision 1
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Table B.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.304Rev1 (Flavour Industry, 2008a; Flavour Industry, 2008b; Flavour 
Industry, 2009; Flavour Industry, 2010) 
FL-no Food  Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
16.117 - 
- 
- 
- 
- 
- 
- 
- 
- 
- 
150 
250 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
1 
5 
0 
0 
- 
- 
- 
- 
16.118 - 
- 
- 
- 
- 
- 
- 
- 
- 
- 
80 
150 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
1 
5 
0 
0 
- 
- 
- 
- 
16.123 0,5 
5 
0,5 
10 
0,5 
10 
0,5 
5 
0 
0 
1 
20 
0,5 
5 
0,5 
5 
- 
- 
- 
- 
0,5 
10 
1 
20 
1 
20 
- 
- 
0,1 
1 
0,2 
1 
- 
- 
- 
- 
16.124 - 
- 
- 
- 
- 
- 
10 
30 
10 
30 
220 
800 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
10 
40 
0 
0 
- 
- 
- 
- 
16.125 - 
- 
- 
- 
- 
- 
20 
100 
20 
100 
70 
300 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
10 
50 
0 
0 
- 
- 
- 
- 
*All four candidate substances are also used in chewing gum, which is not covered by any of the above food categories. Normal/maximum use levels for chewing gum is 200/800 mg/kg for [FL-
no: 16.117], 100/300 mg/kg for [FL-no: 16.118], 30/300 mg/kg for [FL-no: 16.123] and 400/800 mg/kg for [FL-no: 16.125].For the two substances [FL-no: 16.117 and 16.118] the Industry has 
informed that only 10 % of the amount added is released from the chewing gum (Sostmann, 2006). For [FL-no: 16.125] there is a release of 10.5 % (Flavour Industry, 2009). For the remaining 
substance [FL-no: 16.123] there is no information on % release and 100% is used in the calculation. Taking these % releases and an intake estimate of 2 g chewing gum/day into consideration, 
the mTAMDI of the candidate substances based on the 16 food categories and the use of chewing gum is calculated. These figures are presented in Tables B.2.3 and 3.  
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The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as 
outlined in Commission Regulation (EC) No 1565/2000 (EC, 2000) and reported by the Flavour 
Industry in the following way (see Table B.2.2): 
•  Beverages (SCF, 1995) correspond to food category 14.1 
•  Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 
16 
•  Exception a (SCF, 1995) corresponds to food category 5 and 11  
•  Exception b (SCF, 1995) corresponds to food category 15  
•  Exception c (SCF, 1995) corresponds to food category 14.2  
•  Exception d (SCF, 1995) corresponds to food category 12  
•  Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
Table B.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 
(EC, 2000) into the seven SCF food categories used for TAMDI calculation (SCF, 1995). 
  Food categories according to Commission Regulation 1565/2000  Distribution of the seven SCF food 
categories 
Key Food  category  Food Beverages
  Exceptions 
01.0  Dairy products, excluding products of category 02.0  Food     
02.0  Fats and oils, and fat emulsions (type water-in-oil)  Food     
03.0  Edible ices, including sherbet and sorbet  Food     
04.1 Processed  fruit  Food     
04.2  Processed vegetables (incl. mushrooms & fungi, roots & tubers, 
pulses and legumes), and nuts & seeds 
Food    
05.0 Confectionery      Exception  a 
06.0  Cereals and cereal products, incl. flours & starches from roots & 
tubers, pulses & legumes, excluding bakery 
Food    
07.0 Bakery  wares  Food     
08.0  Meat and meat products, including poultry and game  Food     
09.0  Fish and fish products, including molluscs, crustaceans and 
echinoderms  
Food    
10.0  Eggs and egg products  Food     
11.0  Sweeteners, including honey      Exception a 
12.0  Salts, spices, soups, sauces, salads, protein products, etc.       Exception d 
13.0 Foodstuffs  intended for particular nutritional uses  Food     
14.1  Non-alcoholic ("soft") beverages, excl. dairy products    Beverages   
14.2  Alcoholic beverages, incl. alcohol-free and low-alcoholic 
counterparts 
   Exception  c 
15.0  Ready-to-eat savouries      Exception b 
16.0  Composite foods (e.g. casseroles, meat pies, mincemeat) - foods 
that could not be placed in categories 01.0 - 15.0
Food    
 
The mTAMDI values (see Table B.2.3) are presented for each of the five flavouring substances in the 
present Flavouring Group Evaluation, for which Industry has provided use and use levels (Flavour 
Industry, 2008a; Flavour Industry, 2008b; Flavour Industry, 2009; Flavour Industry, 2010). The 
mTAMDI values are only given for the highest reported normal use levels. Flavouring Group Evaluation 304 Revision 1
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TableB.2.3 Estimated intakes based on the mTAMDI approach. 
FL-no  EU Register name  mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of 
concern 
(µg/person/day) 
16.117 N-p-Benzeneacetonitrile-menthanecarboxamide  4400  Class  III  90 
16.118 N-(2-(Pyridine-2-yl)ethyl)-3-p-
menthanecarboxamide 
2500 Class  III  90 
16.123 (1R,2S,5R)-N-(4-Methoxyphenyl)-5-methyl-2-
(1-methylethyl)cyclohexanecarboxamide 
150 Class  III  90 
16.124 (1R,2S,5R)-N-Cyclopropyl-5-methyl-2-
isopropyl cyclohexanecarboxamide 
11000 Class  III  90 
16.125 (2S,5R)-N-[4-(2-Amino-2-oxoethyl)phenyl]-5-
methyl-2-(propan-2-
yl)cyclohexanecarboxamide 
7800 Class  III  90 
 
The calculation of mTAMDI for the candidate substances takes into account the information Industry 
has provided on release from the chewing gum matrix (Flavour Industry, 2009; Flavour Industry, 
2010; Sostmann, 2006). 
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APPENDIX C: METABOLISM  
The hydrolysis of [
14C]-N-p-benzenenitrile-menthanecarboxamide (BMC) [FL-no: 16.117] was 
studied in rat and human hepatic microsomes (Sipes and Kong, 2012). As a positive control the 
hydrolysis of isoeugenol acetate, a known substrate of carboxyl esterase, was used. The radiochemical 
purity of [
14C]-BMC [FL-no: 16.117] were > 99 %.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C.1. The structure of [
14C]-N-p-benzenenitrile-menthanecarboxamide [FL-no: 16.117], with location of the [
14C] label 
(*). 
 
The hydrolytic assay was carried out in a total volume of 0.4 ml of 0.1 M potassium phosphate buffer 
with pH 7.4 containing [
14C]-BMC (100 µM or 20 µM) or isoeugenol acetate (500 µM) and pooled 
hepatic microsomes from male F-344 rats or male humans. At each time point (5, 10, 30 and 60 min.) 
an aliquot of the reaction mixture was removed from the incubation and mixed with ice cold ethanol to 
terminate the reaction. The [
14C]-BMC and its metabolites were analysed with a reversed phase 
HPLC-radiometric analysis. Control incubations were conducted with heat denatured microsomes. No 
hydrolysis was detected at any time point when either active or heat-inactivated hepatic microsomes 
were used. Both hepatic microsomes from rat and humans hydrolysed isoeugenol acetate to 
isoeugenol.  
The results show that metabolically active male rat or human microsomes did not hydrolyse N-p-
benzenenitrile-menthanecarboxamide [FL-no: 16.117]. 
The hydrolysis of a substance with partial structure similarity to [FL-no: 16.117] from FGE.94Rev1, 
N-[(ethoxycarbonyl)methyl]-p-menthane-3-carboxamide [FL-no: 16.111], was studied in artificial 
pancreatic juice and rat liver homogenate (Poet et al., 2005). Based on the disappearance of the 
employed substrate, [FL-no: 16.111] was hydrolysed in artificial pancreatic juice with a half-life of 43 
± 14.7 min. and a first order rate constant (K) of 1.06 ± 0.426 hour
-1. In 20 fold-diluted liver 
homogenate the disappearance of [FL-no: 16.111] was considerably faster (half-life: 0.802 ±0.191 
min.). However, the potential hydrolysis products p-menthane-3-carboxylic acid, glycine ethylester 
and glycine were only detected at trace levels. This indicates that the disappearance of [FL-no: 16.111] 
under the employed in vitro-conditions is due to the hydrolysis of the ethyl ester bond rather than the 
hydrolysis of the amide bond. 
The possible release of cyanide from the candidate substance N-p-benzenenitrile-
menthanecarboxamide [FL-no: 16.117] during metabolism was studied in rat and human hepatocytes. 
Incubations of up to 250 µM of the candidate substance with human or rat hepatocytes for up to 4 
hours only resulted in release of low amounts, if any, of cyanide. Proper positive control incubations 
with benzyl nitrile and sodium cyanide were included in the study (Wolff and Skibbe, 2007). 
N
NH
O
CH3
C H3 CH3
*
N
NH
O
CH3
C H3 CH3
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Specific information regarding absorption, distribution, metabolism and excretion is not available for 
the remaining candidate substances.  
The candidate aromatic amides are anticipated to being absorbed from the gastrointestinal tract like 
other aromatic amides. Aromatic amides are expected to be metabolised to polar metabolites which are 
eliminated in the urine or bile (James, 1974; Schwen, 1982).  
Data on the candidate substance [FL-no: 16.117] and the carboxamide [FL-no: 16.111] demonstrate 
that there is no hydrolysis of the amide bond under the in vitro conditions. Owing to the lack of further 
data the candidate substances cannot be anticipated to be metabolised to innocuous products Flavouring Group Evaluation 304 Revision 1
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ABBREVIATIONS 
ALAT   Alanin  Transaminase 
ASAT   Aspartate  Transaminase 
BW   Body  Weight 
CAS    Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids  
CAS  Chemical Abstract Service 
CoE   Council  of  Europe 
EC     European  Commission 
EFSA    The European Food Safety Authority 
EU   European  Union 
FAO    Food and Agriculture Organization of the United Nations  
FEMA    Flavor and Extract Manufacturers Association 
FGE    Flavouring Group Evaluation  
FLAVIS (FL)  Flavour Information System (database) 
FOB   Functional  Observational  Battery 
HPLC    High Performance Liquid Chromatography 
ID     Identity 
IOFI   International  Organization of the Flavour Industry 
JECFA   The Joint FAO/WHO Expert Committee on Food Additives 
LD50   Lethal Dose, 50 %; Median lethal dose 
MA   Motor  Activity 
MCH   Mean  Corpuscular  Hemoglobin 
MCV   Mean  Corpuscular  Volume 
MSDI    Maximised Survey-derived Daily Intake 
mTAMDI  Modified Theoretical Added Maximum Daily Intake 
No     Number 
NOAEL  No Observed Adverse Effect Level 
OECD   Organisation for Economic Co-operation and Development 
SCF    Scientific Committee on Food 
TAMDI  Theoretical Added Maximum Daily Intake 
TSH   Thyroid-stimulating  hormone 
UDP   Uridine  Diphosphate 
UGT   UDP  Glucuronyltransferase 
WHO   World  Health  Organisation 